TAKE Solutions Ltd. Ltd.announced that it has entered into definitive agreements to acquire a Life Sciences Services player, Ecron Acunova (EA) for Rs.115 cr.
This association will enable TAKE add expertise in the areas of Biosimilars, Regenerative Medicine and Diagnostic imaging agents space which are emerging growth areas. This will help TAKE move the addressable market for its services to 30 bn $. It will also significantly enhance presence in Europe and Nordic countries, according to a press statement by the company.
Srinivasan H.R., Vice Chairman & Managing Director, TAKE Solutions said, “Globally, there is a growing focus on quality, data, analytics and outcomes in the industry, resulting in increased pharma/biotech R&D spending and funding. This acquisition will enhance our addressable market from 15.9 bn $ to over 30 bn $ by 2019, giving us great headroom for growth.” He further added, “TAKE & EA’s combined attributes will strengthen our position as a fully integrated differentiated Life Sciences services provider to large and small global pharmaceutical companies and thereby broaden the addressable market.
— Press Release Watch (@PrReleaseWatch) November 18, 2015
This association will enable TAKE add expertise in the areas of Biosimilars, Regenerative Medicine and Diagnostic imaging agents space which are emerging growth areas. This will help TAKE move the addressable market for its services to 30 bn $. It will also significantly enhance presence in Europe and Nordic countries, according to a press statement by the company.
Srinivasan H.R., Vice Chairman & Managing Director, TAKE Solutions said, “Globally, there is a growing focus on quality, data, analytics and outcomes in the industry, resulting in increased pharma/biotech R&D spending and funding. This acquisition will enhance our addressable market from 15.9 bn $ to over 30 bn $ by 2019, giving us great headroom for growth.” He further added, “TAKE & EA’s combined attributes will strengthen our position as a fully integrated differentiated Life Sciences services provider to large and small global pharmaceutical companies and thereby broaden the addressable market.
